10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed

Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects

IlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo Finance

FierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.st

FierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes

Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease

CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation

CellReplaying germinal center evolution on a quantified affinity landscape

CellXenophagocytosis blockade enhances interspecies chimerism

FierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy

Endpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetes

Endpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this year